Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

Sales of GLP1 therapy tirzepatide marketed as Mounjaro for diabetes and Zepbound ... However Type 2 diabetes medication Trulicity saw sales decline 25% year-over-year to $1.3 billion due to ...

New Products revenue grew by $3.15 billion to $5.64 billion in Q4 2024, led by Zepbound and Mounjaro. Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance ...

LLY’s GLP-1 therapy tirzepatide, branded as Mounjaro and Zepbound for diabetes ... Meanwhile, sales from Type 2 diabetes medication Trulicity fell ~25% YoY to $1.3B amid competitive headwinds ...

Zepbound and Mounjaro were again the largest growth contributors, partially offset by declines in Trulicity. Realized prices decrease 5% in the U.S. due to favorable changes to estimate for ...

1 Lilly defines new products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Kisunla, Mounjaro ... Taltz, Trulicity, Tyvyt and Verzenio.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...